Editor's Choice
Modulating the Preterm Gut Microbiota: An Interview with Dr Lindsay Hall
Dr Lindsay Hall of the Quadram Institute talks to us about the preterm infant gut microbiota and its modulation.
Microbiome Times
Finance
Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that the Opposition Division of the European Patent Office has upheld Vedanta’s […]
Finance
Seres Therapeutics First Quarter Financial Results and Clinical Pipeline Progress
Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by […]
Pharma & Human Health
4D Pharma Clinical Update on MRx0518 Oncology Programmes
The first patient participating in the combination phase I/II study of MRx0518 and *KEYTRUDA® in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA and 4D’s strategic collaboration with MD Anderson has completed Cycle 1 […]
Pharma & Human Health
Finch Therapeutics Receives Fast Track Designation for the Investigation of Microbiota Treatment for Children with Autism Spectrum Disorder
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children […]
Pharma & Human Health
DuPont to Provide Probiotics for International Pediatric Sepsis Research
It is estimated that nearly 3 million newborns and 1.2 million children suffer from sepsis globally each year, with limited effective forms of prevention currently available. To help combat this, DuPont Nutrition & Biosciences (DuPont), […]
Pharma & Human Health
Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced the initiation of pre-clinical studies for BMC-121 & BMC-127, two rationally-designed microbial consortia, in its therapeutic […]
Finance
Flagship Pioneering Unveils Kintai Therapeutics
Kintai is pioneering precision therapeutics based on enteric signaling networks in the human body Flagship Pioneering, a unique life science innovation enterprise, today unveiled Kintai Therapeutics and named Paul-Peter Tak, M.D., Ph.D., as president, chief […]
Pharma & Human Health
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD
MaaT Pharma announced that the independent Data and Safety Monitoring Board (DSMB) recommended the continuation, without amendment, of the ongoing Phase II HERACLES study (NCT03359980). The HERACLES trial investigates the use of lead biotherapeutic MaaT013 […]
Pharma & Human Health
SkinBiotix® Shows Efficacy in First Human Study
SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, provides the results of its first human study. The study was primarily undertaken to show the effects of […]
Pharma & Human Health
C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage
C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on bacteriophage, announced that the United States Patent and Trademark Office (USPTO) has issued patent No. […]